HER2+ Breast Cancer | Specialty

Pathologist's Role in Genetic Testing for Breast Cancer

February 25th 2015

Role of Genetic Testing in Breast Cancer

February 25th 2015

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Swain Discusses Final Survival Analysis of CLEOPATRA Study

February 24th 2015

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

Unprecedented OS Benefit Cements Pertuzumab Regimen as Frontline Standard in HER2-Positive MBC

February 20th 2015

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

Finn Discusses Clinical Implications of Palbociclib Approval for MBC

February 10th 2015

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

Lackluster T-DM1 Results Surprise Perez

December 22nd 2014

Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings

Frontline T-DM1 Results Disappointing in Phase III MARIANNE Trial

December 19th 2014

Two HER2-targeting regimens anchored by T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer in the MARIANNE trial, dealing a blow to efforts to move the drug into frontline settings.

A New World of Targeted Therapies for HER2-Positive Breast Cancer Takes Shape

December 17th 2014

When added to standard chemotherapy, trastuzumab not only dramatically improved disease-free survival rates for patients with metastatic disease, but also resulted in a clear survival advantage unprecedented for most treatments of metastatic breast cancer.

Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels

December 10th 2014

Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Updated Data Continues to Support Adjuvant Trastuzumab

November 20th 2014

Adding 1-year of adjuvant trastuzumab to chemotherapy continues to demonstrate an improvement in overall survival (OS) and disease-free survival (DFS) for patients with early-stage HER2-positive breast cancer

Frontline T-DM1 on Horizon in Metastatic Breast Cancer

November 20th 2014

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

Fewer CNS Metastases, Similar Efficacy Seen With Neratinib Versus Trastuzumab

November 14th 2014

Frontline treatment with neratinib in combination with paclitaxel demonstrated similar ORR and PFS as the combination of trastuzumab and paclitaxel while lowering the incidence of CNS metastases in patients with locally recurrent or metastatic HER2-positive breast cancer.

Dr. Mamounas on Selecting Patients With Breast Cancer for Neoadjuvant Chemotherapy

October 23rd 2014

Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.

Expert Says pCR Data Support Neoadjuvant Therapy in HER2-Positive Breast Cancer

October 22nd 2014

Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care

Dr. Swain on the Impact of Chemotherapy on Outcomes in HER2-Positive Metastatic Breast Cancer

October 15th 2014

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses a taxane's impact on outcomes in patients with HER2-positive metastatic breast cancer.

New Tactics Needed for Adjuvant Therapy to Advance in Early HER2-Positive Breast Cancer

October 8th 2014

Recent research has shown that adding targeted agents to trastuzumab-based chemotherapy regimens in the adjuvant setting may not significantly improve outcomes in patients with early-stage HER2-positive breast cancer.

Swain Provides Insight Into Updated CLEOPATRA Survival Findings

October 5th 2014

Pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median overall survival (OS) by 15.7 months over standard first-line therapy

Tumor Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer

October 2nd 2014

A high level of tumor infiltrating lymphocytes (TILs) may be a marker of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer, especially in patients with triple-negative or HER2-positive disease